Impax Asset Management Group plc Sells 181,377 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Impax Asset Management Group plc reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 90.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,826 shares of the medical research company's stock after selling 181,377 shares during the period. Impax Asset Management Group plc's holdings in IQVIA were worth $3,495,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Sowell Financial Services LLC acquired a new stake in IQVIA during the first quarter valued at $305,000. Mather Group LLC. increased its stake in shares of IQVIA by 83.5% in the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after purchasing an additional 350 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in IQVIA in the 4th quarter worth about $60,000. Park Avenue Securities LLC grew its holdings in IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock valued at $956,000 after purchasing an additional 1,562 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of IQVIA by 34.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock worth $2,338,000 after buying an additional 3,398 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IQV has been the subject of several recent research reports. UBS Group reduced their price objective on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Barclays lowered their price objective on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. Redburn Partners set a $188.00 target price on IQVIA in a report on Friday, May 23rd. Robert W. Baird cut their price target on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Finally, Citigroup reiterated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $1.67 on Monday, hitting $162.57. The company's stock had a trading volume of 1,489,122 shares, compared to its average volume of 1,652,666. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The company has a market capitalization of $28.12 billion, a price-to-earnings ratio of 22.15, a price-to-earnings-growth ratio of 1.82 and a beta of 1.30. The stock's 50-day moving average is $150.86 and its two-hundred day moving average is $173.03. The company has a debt-to-equity ratio of 2.19, a quick ratio of 0.82 and a current ratio of 0.82.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. The business had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the firm posted $2.54 earnings per share. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.